Simmunext Biotherapeutics Overview

  • Year Founded
  • 2022

Year Founded

  • Status
  • Private

  • Employees
  • 3

Employees

  • Latest Deal Type
  • Early Stage VC

  • Investors
  • 4

Simmunext Biotherapeutics General Information

Description

Developer of polymer-based immunofilament therapeutics designed to restore and enhance immune function in cancer and other diseases. The company leverages a proprietary nanotechnology platform by combining cutting-edge polymer chemistry, tumor immunology and industrial drug development expertise to mimics natural immune cell activity for the treatment of cancer, autoimmune disorders and infectious diseases, enabling healthcare institutions to improve clinical outcomes and broaden patient access to advanced immunotherapies.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Geert Grooteplein Zuid 10
  • Nijmegen
  • Netherlands
Primary Industry
Biotechnology
Corporate Office
  • Geert Grooteplein Zuid 10
  • Nijmegen
  • Netherlands

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Simmunext Biotherapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC 09-Aug-2023 Completed Startup
1. Early Stage VC (Series 1) 01-Jan-2022 Completed Startup
To view Simmunext Biotherapeutics’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Simmunext Biotherapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Simmunext Biotherapeutics Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
VFF Gelderland Corporation Minority
Oncode Oncology Bridge Fund Venture Capital Minority
Radboud University University Minority
Radboud university medical center Corporation Minority
To view Simmunext Biotherapeutics’s complete investors history, request access »

Simmunext Biotherapeutics FAQs

  • When was Simmunext Biotherapeutics founded?

    Simmunext Biotherapeutics was founded in 2022.

  • Where is Simmunext Biotherapeutics headquartered?

    Simmunext Biotherapeutics is headquartered in Nijmegen, Netherlands.

  • What is the size of Simmunext Biotherapeutics?

    Simmunext Biotherapeutics has 3 total employees.

  • What industry is Simmunext Biotherapeutics in?

    Simmunext Biotherapeutics’s primary industry is Biotechnology.

  • Is Simmunext Biotherapeutics a private or public company?

    Simmunext Biotherapeutics is a Private company.

  • What is Simmunext Biotherapeutics’s current revenue?

    The current revenue for Simmunext Biotherapeutics is .

  • Who are Simmunext Biotherapeutics’s investors?

    VFF Gelderland, Oncode Oncology Bridge Fund, Radboud University, and Radboud university medical center have invested in Simmunext Biotherapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process